Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Combined treatment with valproic acid and ATRA can be used to achieve disease
stabilization for a subset of patients with acute myelogenous leukemia (AML), and this effect
can be improved without serious toxicity by adding low-dose cytarabine to this treatment.
Adult patients >18 years of age who can be included:
Elderly patients who cannot achieve standard chemotherapy, patients with relapsed or
resistant AML.
Treatment: Combined therapy with:
Valproic acid, continuous therapy until disease progression ATRA, oral therapy for 14 days
every three months Low-dose cytarabine 10 mg/m2 up to 10 injections during week 2 and 3,
repeated every 3 months.